This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock (Revised)
by Zacks Equity Research
Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, in combination with the other party's Opdivo and Opdivo plus Yervoy.
Nektar, Bristol-Myers Tie-Up for Cancer Combos Drives Stock
by Zacks Equity Research
Nektar (NKTR) inks a joint global collaboration deal with Bristol-Myers to develop and commercialize its cancer candidate, NKTR-214, combined with the other party's Opdivo and Opdivo plus Yervoy.
Nektar (NKTR) Surges: Stock Moves 11% Higher
by Zacks Equity Research
Nektar (NKTR) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.
5 Best-Performing Stocks of the Top ETF of January
by Sweta Killa
Inside the top performing stocks of the top biotech ETF of January.
Here's Why Nektar Stock Skyrocketed Almost 500% in a Year
by Zacks Equity Research
Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.
Nektar Boasts Strong Pipeline, Competition Remains a Woe
by Zacks Equity Research
Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.
Why is Nektar (NKTR) Stock Up More Than 350% This Year?
by Zacks Equity Research
Nektar's (NKTR) shares soar in the year so far on a robust pipeline including several study initiations and strategic collaborations.
Can Nektar Therapeutics (NKTR) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Nektar Therapeutics (NKTR) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Is the Options Market Predicting a Spike in Nektar (NKTR) Stock?
by Zacks Equity Research
Investors in Nektar (NKTR) need to pay close attention to the stock based on moves in the options market lately.
Nektar (NKTR) Stock Up More than 300% This Year: Here's Why
by Zacks Equity Research
Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.
Company News For Nov 14, 2017
by Zacks Equity Research
Companies in the news are: TSN,JD,NKTR,GGP
Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II
by Zacks Equity Research
Nektar (NKTR) and partner Bristol-Myers share positive interim data from dose-escalation part of a phase I/II study, evaluating NKTR-214 with Opdivo across three tumor types.
Nektar (NKTR) Q3 Earnings & Sales Surpass, Sales View Up
by Zacks Equity Research
Nektar's (NKTR) earnings and revenues beat estimates in Q3. The company also raises its revenue guidance for the same period.
Nektar Therapeutics (NKTR) Jumps: Stock Rises 10.54%
by Zacks Equity Research
Nektar Therapeutics (NKTR) was a big mover last session, as the company saw its shares nearly 11% on the day amid huge volumes.
Implied Volatility Surging for Nektar (NKTR) Stock Options
by Zacks Equity Research
Nektar (NKTR) needs investors to pay close attention to the stock based on moves in the options market lately.
Nektar's Lead Drugs Drive Growth, Partner Reliance a Woe
by Zacks Equity Research
Nektar (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.
Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate
by Zacks Equity Research
Nektar (NKTR) initiates phase I/II combo study on lead candidate NKTR-214 along with Tecentriq and Keytruda. The trial complements Nektar's ongoing PIVOT research clubbed with Opdivo.
Surging Earnings Estimates Signal Good News for Nektar (NKTR)
by Zacks Equity Research
Nektar (NKTR) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Are Options Traders Betting on a Big Move in Nektar (NKTR) Stock?
by Zacks Equity Research
Investors Nektar (NKTR) need to pay close attention to the stock based on moves in the options market lately.
Will Nektar's (NKTR) Candidates Enhance Growth in 2017?
by Zacks Equity Research
Nektar Therapeutics (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.
Nektar's (NKTR) Shares Fall Post Wider Q2 Loss, Revenues Lag
by Zacks Equity Research
Nektar (NKTR) reports wider-than-expected loss with revenues falling shy of estimates. However, the top line rises year over year, courtesy an increase in product sales and royalty revenues.
Are Options Traders Betting on a Big Move in Nektar (NKTR) Stock?
by Zacks Equity Research
Investors in Nektar Therapeutics (NKTR) need to pay close attention to the stock based on moves in the options market lately.
Nektar's NKTR-181 Positive in Human Abuse Potential Study
by Zacks Equity Research
Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.
Implied Volatility Surging for Nektar Therapeutics (NKTR) Stock Options
by Zacks Equity Research
Nektar Therapeutics (NKTR) needs Investors to pay close attention to the stock based on moves in the options market lately.
5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017
by Zacks Equity Research
London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.